Prostate Imaging Reporting and Data System score (PI-RADS) and Glutathione S-transferase P1 methylation status (GST-P1) in the diagnosis of prostate cancer patients with borderline PSA values

• Published in: Journal of Mind and Medical Sciences Vol. 9; no. 2; pp. 304 - 309
• Main Authors: Stan, Marius, Botnarciuc, Vladimir, Suceveanu, Andra Iulia, Costea, Andreea Cristina, Suceveanu, Adrian Paul, Mazilu, Laura, Iorga, Ciprian, Hangan, Tony, Tudor, Corneliu, Epistatu, Dragos, Chirila, Sergiu, Gherghina, Viorel, Voinea, Felix
• Format: Journal Article
• Language: English
• Published: MDPI AG 23.10.2022
• Subjects: diagnosis; gst-p1; pi-rads; prostate cancer; prostate-specific antigen
• ISSN: 2392-7674; 2392-7674
• DOI: 10.22543/2392-7674.1354

Objectives. The objective of this study was to evaluate the potential use of Prostate Imaging – Reporting and Data System version 2 (PI-RADS) in combination with Glutathione S-transferase P1 (GST-P1) expression for an improved diagnosis of prostate cancer, in patients with inconclusive values of prostate-specific antigen (PSA). Materials and Methods. The study was conducted on 80 patients for whom PSA values were evaluated and were found to be inconclusive (4-10 ng/ml). These patients underwent imagistic evaluation (PI-RADS), followed by transurethral prostate biopsy, with the evaluation of GST-P1 expression and histopathological examination (for diagnosis confirmation). Results. By combining the results of PI-RADS and GST-P1 the capacity of the tests to correctly identify healthy subjects, with an area under curve of 0,832 (95% CI 0.732–0.907), with a sensitivity of 73,25% and a specificity of 77,78%. Conclusions. PI-RADS lesions and GST-P1 methylation testing when PSA levels are in a “grey zone”, provide a better specificity and sensitivity by comparison through single testing. Testing patients with inconclusive PSA levels allows for a more accurate diagnosis and less over-diagnosis by non-invasive procedures, such as repeated biopsies.